Literature DB >> 1178806

Prevention of recidivism of schizophrenics treated with fluphenazine enanthate.

J del Giudice, W G Clark, E F Gocka.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1975        PMID： 1178806     DOI： 10.1016/s0033-3182(75)71232-x

Source DB:  PubMed          Journal:  Psychosomatics        ISSN： 0033-3182            Impact factor:   2.386


× No keyword cloud information.
  10 in total

1.  What's new in the psychopharmacology of schizophrenia.

Authors:  A Rifkin; F Quitkin
Journal:  Bull N Y Acad Med       Date:  1978-10

2.  The Potential Role of Long-acting Injectable Antipsychotics in People with Schizophrenia and Comorbid Substance Use.

Authors:  Maju Mathew Koola; Heidi J Wehring; Deanna L Kelly
Journal:  J Dual Diagn       Date:  2012

Review 3.  Intramuscular preparations of antipsychotics: uses and relevance in clinical practice.

Authors:  A Cario Altamura; Francesca Sassella; Annalisa Santini; Clauno Montresor; Sara Fumagalli; Emanuela Mundo
Journal:  Drugs       Date:  2003       Impact factor: 9.546

4.  Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants.

Authors:  Giovanni Ostuzzi; Federico Bertolini; Federico Tedeschi; Giovanni Vita; Paolo Brambilla; Lorenzo Del Fabro; Chiara Gastaldon; Davide Papola; Marianna Purgato; Guido Nosari; Cinzia Del Giovane; Christoph U Correll; Corrado Barbui
Journal:  World Psychiatry       Date:  2022-06       Impact factor: 49.548

5.  Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials.

Authors:  Taishiro Kishimoto; Alfred Robenzadeh; Claudia Leucht; Stefan Leucht; Koichiro Watanabe; Masaru Mimura; Michael Borenstein; John M Kane; Christoph U Correll
Journal:  Schizophr Bull       Date:  2012-12-17       Impact factor: 9.306

Review 6.  Fluphenazine (oral) versus placebo for schizophrenia.

Authors:  Hosam E Matar; Muhammad Qutayba Almerie; Stephanie Sampson
Journal:  Cochrane Database Syst Rev       Date:  2013-07-17

Review 7.  Long-term depot antipsychotics. A risk-benefit assessment.

Authors:  T R Barnes; D A Curson
Journal:  Drug Saf       Date:  1994-06       Impact factor: 5.606

Review 8.  Depot antipsychotic drugs. Place in therapy.

Authors:  J M Davis; L Matalon; M D Watanabe; L Blake; L ] Metalon L [corrected to Matalon
Journal:  Drugs       Date:  1994-05       Impact factor: 9.546

9.  Oral versus Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Special Populations at Risk for Treatment Nonadherence: A Systematic Review.

Authors:  Simon Zhornitsky; Emmanuel Stip
Journal:  Schizophr Res Treatment       Date:  2012-02-15

Review 10.  Fluphenazine (oral) versus placebo for schizophrenia.

Authors:  Hosam E Matar; Muhammad Qutayba Almerie; Stephanie J Sampson
Journal:  Cochrane Database Syst Rev       Date:  2018-06-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.